Compare Stocks: KARD, ERAS, GRFS, and DNTH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNTH Dianthus Therapeutics	$84.88 -0.6%	$104.14	$32.22 ▼ $117.88	$4.65B	1.35	929,064 shs	562,470 shs
ERAS Erasca	$14.12 -1.3%	$16.69	$2.11 ▼ $24.28	$4.94B	0.61	5.88 million shs	3.83 million shs
GRFS Grifols	$7.50 -0.3%	$7.71	$6.96 ▼ $9.90	$5.10B	0.7	640,427 shs	260,700 shs
KARD Kardigan	$13.83 +2.5%	$18.94	$12.23 ▼ $27.00	$1.29B	N/A	513,562 shs	1.03 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNTH Dianthus Therapeutics	-3.00%	-2.02%	-21.00%	-12.92%	+147.82%
ERAS Erasca	-2.85%	+0.63%	-11.67%	-24.22%	+513.73%
GRFS Grifols	+1.48%	+3.01%	-3.59%	+2.87%	-21.75%
KARD Kardigan	-11.48%	-7.98%	-35.30%	-39.29%	+1,348,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNTH Dianthus Therapeutics	$84.88 -0.6%	$104.14	$32.22 ▼ $117.88	$4.65B	1.35	929,064 shs	562,470 shs
ERAS Erasca	$14.12 -1.3%	$16.69	$2.11 ▼ $24.28	$4.94B	0.61	5.88 million shs	3.83 million shs
GRFS Grifols	$7.50 -0.3%	$7.71	$6.96 ▼ $9.90	$5.10B	0.7	640,427 shs	260,700 shs
KARD Kardigan	$13.83 +2.5%	$18.94	$12.23 ▼ $27.00	$1.29B	N/A	513,562 shs	1.03 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNTH Dianthus Therapeutics	-3.00%	-2.02%	-21.00%	-12.92%	+147.82%
ERAS Erasca	-2.85%	+0.63%	-11.67%	-24.22%	+513.73%
GRFS Grifols	+1.48%	+3.01%	-3.59%	+2.87%	-21.75%
KARD Kardigan	-11.48%	-7.98%	-35.30%	-39.29%	+1,348,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNTH Dianthus Therapeutics	2.93	Moderate Buy	$129.83	52.96% Upside
ERAS Erasca	2.64	Moderate Buy	$22.09	56.45% Upside
GRFS Grifols	1.67	Reduce	$10.00	33.33% Upside
KARD Kardigan	2.50	Moderate Buy	$42.25	205.50% Upside

Current Analyst Ratings Breakdown

Latest KARD, ERAS, GRFS, and DNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	KARD Kardigan	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D)
9/11/2026	DNTH Dianthus Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$135.00
9/8/2026	ERAS Erasca	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/4/2026	DNTH Dianthus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$156.00
8/25/2026	KARD Kardigan	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$51.00 ➝ $46.00
8/17/2026	GRFS Grifols	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/14/2026	ERAS Erasca	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $20.00
8/13/2026	ERAS Erasca	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $21.00
8/12/2026	ERAS Erasca	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $22.00
8/6/2026	DNTH Dianthus Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$110.00 ➝ $128.00
8/6/2026	DNTH Dianthus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$130.00 ➝ $158.00

(Data available from 10/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNTH Dianthus Therapeutics	$2.04M	2,280.11	N/A	N/A	$11.41 per share	7.44
ERAS Erasca	N/A	N/A	N/A	N/A	$1.05 per share	N/A
GRFS Grifols	$7.42B	0.69	$1.43 per share	5.23	$12.64 per share	0.59
KARD Kardigan	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNTH Dianthus Therapeutics	-$162.34M	-$4.15	N/A	N/A	N/A	-10,096.95%	-22.53%	-21.55%	11/5/2026 (Estimated)
ERAS Erasca	-$124.55M	-$0.95	N/A	N/A	N/A	N/A	-38.43%	-32.05%	11/11/2026 (Estimated)
GRFS Grifols	$454.82M	$0.19	39.47	5.60	0.27	5.54%	6.21%	2.39%	11/10/2026 (Estimated)
KARD Kardigan	-$191.94M	-$2.88	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest KARD, ERAS, GRFS, and DNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ERAS Erasca	-$0.1114	-$0.14	-$0.0286	-$0.14	N/A	N/A
8/11/2026	Q2 2026	KARD Kardigan	N/A	-$4.61	N/A	-$4.61	N/A	N/A
8/4/2026	Q2 2026	DNTH Dianthus Therapeutics	-$0.8463	-$0.90	-$0.0537	-$0.90	$0.30 million	$0.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
GRFS Grifols	$0.08	1.07%	N/A	42.11%	N/A
KARD Kardigan	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNTH Dianthus Therapeutics	N/A	26.10	26.10
ERAS Erasca	N/A	8.29	8.29
GRFS Grifols	1.10	2.37	0.81
KARD Kardigan	N/A	8.72	8.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNTH Dianthus Therapeutics	47.53%
ERAS Erasca	67.78%
GRFS Grifols	N/A
KARD Kardigan	N/A

Insider Ownership

Company	Insider Ownership
DNTH Dianthus Therapeutics	3.02%
ERAS Erasca	14.20%
GRFS Grifols	0.19%
KARD Kardigan	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNTH Dianthus Therapeutics	92	54.80 million	53.14 million	Optionable
ERAS Erasca	103	349.76 million	300.10 million	Optionable
GRFS Grifols	25,247	680.58 million	679.28 million	Optionable
KARD Kardigan	241	93.50 million	N/A	N/A

KARD, ERAS, GRFS, and DNTH Headlines

Recent News About These Companies

KARD’s Danicamtiv Trial Progress Puts Genetic Heart Failure in Investor Focus

October 5 at 12:30 PM | tipranks.com

Kardigan, Inc. Announces Director Resignation and Appoints Kristin Reinke as New Audit Committee Chair

October 2, 2026 | kalkinemedia.comK

Kardigan, Inc. Announces Board and Committee Changes, Effective September 29, 2026

October 1, 2026 | marketscreener.comM

KARDIGAN INC, 구글 재무 부사장 라인케 이사 선임..감사위원장 맡는다

September 30, 2026 | mk.co.krM

Kardigan Announces Appointment of Kristin Reinke to its Board of Directors

September 30, 2026 | marketscreener.comM

Kardigan, Inc. (NASDAQ:KARD) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 30, 2026 | americanbankingnews.com

Kardigan, Inc. (NASDAQ:KARD) Stock Has Consensus Price Target of $42.25 According to Analysts

September 30, 2026 | marketbeat.com

Kardigan: Funded Precision Cardiology Offers More Than Pipeline Diversification

September 13, 2026 | seekingalpha.com

Citadel Advisors LLC Acquires Shares of 120,000 Kardigan, Inc. $KARD

September 9, 2026 | marketbeat.com

Kardigan to Present at Two September Investor Conferences

September 2, 2026 | businesswire.com

Kardigan’s Danicamtiv Heart Study Moves Forward, Keeping KARD on Investors’ Radar

September 2, 2026 | tipranks.com

Kardigan Inc (KARD) Stock Price, Quote, News & History

August 20, 2026 | benzinga.com

Kardigan: Q2 Earnings Snapshot

August 11, 2026 | stamfordadvocate.comS

Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates

August 11, 2026 | aol.comA

We've developed a first-of-its-kind medicine to battle cardiovascular disease: Kardigan CEO

June 26, 2026 | msn.com

Kardigan (NASDAQ:KARD) Director Purchases $20,000,000.00 in Stock

June 25, 2026 | insidertrades.com

How Kardigan spun deal leftovers into a $400M IPO

June 24, 2026 | finance.yahoo.com

Biotech stock Kardigan shows new rules of biotech investment

June 24, 2026 | msn.com

Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

June 22, 2026 | businesswire.com

Kardigan Begins Process For IPO On Cardiovascular Treatments Promise

June 2, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KARD, ERAS, GRFS, and DNTH Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

$84.88 -0.52 (-0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$84.92 +0.05 (+0.05%)

As of 04:15 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Erasca NASDAQ:ERAS

$14.12 -0.18 (-1.26%)

Closing price 04:00 PM Eastern

Extended Trading

$14.19 +0.07 (+0.49%)

As of 05:26 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Grifols NASDAQ:GRFS

$7.50 -0.02 (-0.27%)

Closing price 04:00 PM Eastern

Extended Trading

$7.50 0.00 (0.00%)

As of 04:15 PM Eastern

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Kardigan NASDAQ:KARD

$13.83 +0.34 (+2.52%)

As of 04:00 PM Eastern

Kardigan Inc. is a clinical-stage precision therapeutics company developing medicines which target the root cause of specific cardiovascular diseases. Kardigan Inc. is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KARD, ERAS, GRFS, and DNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KARD, ERAS, GRFS, and DNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KARD, ERAS, GRFS, and DNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KARD, ERAS, GRFS, and DNTH Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

Erasca NASDAQ:ERAS

Grifols NASDAQ:GRFS

Kardigan NASDAQ:KARD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KARD, ERAS, GRFS, and DNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KARD, ERAS, GRFS, and DNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KARD, ERAS, GRFS, and DNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KARD, ERAS, GRFS, and DNTH Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

Erasca NASDAQ:ERAS

Grifols NASDAQ:GRFS

Kardigan NASDAQ:KARD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools